Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
CAMBRIDGE, MA - Moderna, Inc. (NASDAQ:MRNA), currently trading near its 52-week low of $23.76, announced its participation in the upcoming European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress, set to take place in Vienna, Austria, from April 11-15, 2025. The biotechnology company, which InvestingPro analysis suggests is currently undervalued, will present twelve scientific studies, advancing its research in various infectious diseases, including COVID-19, influenza, and RSV.
At the congress, Moderna will share findings from three oral presentations and nine poster presentations, including an e-poster. The research covers the immunogenicity and safety of its mRNA vaccines against different pathogens. Among the highlighted studies is the evaluation of mRNA COVID-19 vaccines designed to target specific SARS-CoV-2 sublineages, with presentations scheduled for April 12 and 13. According to InvestingPro data, the company maintains a strong financial position with more cash than debt and a healthy current ratio of 3.67, though analysts anticipate sales decline in the current year.
Other significant research includes the long-term safety and immunogenicity of Moderna’s cytomegalovirus (CMV) mRNA-1647 vaccine, with 36-month results from a phase 2 extension trial to be presented on April 15. Additionally, an interim analysis from a Phase 1/2 Trial of Moderna’s mRNA mpox vaccine candidate will be shared on April 14.
Moderna’s presence at the ESCMID Global Congress underscores its commitment to advancing mRNA technology in the infectious disease space. The company’s mRNA platform has facilitated the development of vaccines and therapeutics for a range of diseases, including its widely-recognized COVID-19 vaccine.
The press release also contains forward-looking statements regarding the potential of Moderna’s vaccine candidates to impact disease outcomes. However, these statements are not guarantees and are subject to risks and uncertainties that could cause actual results to differ.
This announcement is based on a press release statement from Moderna, Inc. and does not imply endorsement of the company’s claims. The information presented is intended to provide a factual report of Moderna’s research activities as they prepare to participate in the ESCMID Global Congress.
In other recent news, Moderna Inc. has seen significant developments impacting its business landscape. The company announced that its mRNA-based vaccine, mRESVIA® (mRNA-1345), received approval from the Australian Therapeutic Goods Administration for preventing respiratory syncytial virus (RSV) in older adults. This approval follows a successful Phase 3 clinical trial and marks the first mRNA vaccine authorized in Australia for a condition other than COVID-19. Additionally, Brookline Capital Markets maintained a Buy rating on Moderna stock with a price target of $212, highlighting the vaccine’s competitive edge for the upcoming RSV season.
However, Moderna faces challenges following the ousting of Dr. Peter Marks, the FDA’s top vaccine official, which has stirred concerns about potential changes in the regulatory environment. Dr. Marks’ departure has led to apprehension among investors regarding the FDA’s future approach to vaccine approvals. The situation has been further complicated by the U.S. government’s decision to cut financial support for Gavi, the Vaccine Alliance, potentially affecting future vaccine demand in developing countries.
These developments have contributed to fluctuations in Moderna’s market position, as the company navigates both opportunities and uncertainties in the global vaccine landscape. Investors remain attentive to how these factors may influence Moderna’s growth and strategic direction moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.